The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

It was the first company to receive FDA approval, in December 2023, for Casgevy – a genome-edited cell therapy for sickle-cell disease and another blood disorder, beta thalassaemia. These are ...

The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well. Investing in stocks that aren't performing well can be a good move, but only if there are good reasons ...

The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well. Investing in stocks that aren't performing well can be a good move, but only if there are good reasons ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE ...

Casgevy was approved in the UK and US in late-2023, and involves editing the patient’s haematopoietic stem cells to increase the production of foetal haemoglobin, which prevents the sickling of red ...

successfully utilizing Casgevy gene therapy through CRISPR gene editing technology to treat a 13-year-old patient with thalassemia major. The achievement is the first of its kind outside of clinical ...

After hours: 7:53:24 p.m. EST Loading Chart for VRTX ...

Pre-market: 4:30:04 am GMT-5 ...

After hours: 7:57:05 pm GMT-5 Loading Chart for CRSP ...